Table 1.
Controls | Patients with CCS | p-value | |
---|---|---|---|
(n=26) | (n=68) | ||
Clinical data | |||
Age, years | 61.3 (9.4) | 64.8 (9.3) | 0.099 |
Male, n (%) | 23 (88.5) | 61 (89.7) | 1.000 |
Hypertension, n (%) | 14 (53.8) | 64 (94.1) | <0.001 |
Dyslipidemia, n (%) | 18 (69.2) | 65 (95.6) | <0.001 |
Diabetes mellitus, n (%) | 3 (11.5) | 29 (42.6) | 0.007 |
Smoking history (current or past), n (%) | 6 (23.1) | 37 (54.4) | 0.006 |
Previous coronary artery bypass grafting, n (%) | 0 (0.0) | 23 (33.8) | <0.001 |
Left ventricular ejection fraction > 50%, n (%) | 26 (100.0) | 68 (100.0) | - |
Antiplatelet agent, n (%) | 6 (23.1) | 66 (97.1) | <0.001 |
Statin therapy, n (%) | 13 (50.0) | 61 (89.7) | <0.001 |
Laboratory data | |||
Hemoglobin, g/dL | 13.9 (1.3) | 13.6 (1.6) | 0.380 |
Leukocyte count, 10^9/L | 6.4 (1.7) | 7.6 (1.8) | 0.012 |
Neutrophil count, 10^9/L | 3.5 (1.5) | 4.4 (1.5) | 0.010 |
Lymphocyte count, 10^9/L | 2.0 (0.5) | 2.1 (0.8) | 0.722 |
Neutrophil/lymphocyte ratio | 1.9 (0.7) | 2.4 (1.1) | 0.029 |
Platelet count, 10^9/L | 230.1 (58.8) | 222.6 (51.1) | 0.546 |
Fasting glycaemia, mg/dL | 95.3 (35.1) | 112.7 (52.5) | 0.124 |
Percentage of glycosylated hemoglobin | 5.8 (1.2) | 6.4 (1.5) | 0.014 |
Creatinine, mg/dL | 0.8 (0.2) | 1.0 (0.3) | 0.001 |
Total cholesterol, mg/dL | 186.0 (50.7) | 166.4 (45.9) | 0.082 |
LDL-cholesterol, mg/dL | 111.3 (44.2) | 100.9 (37.7) | 0.261 |
HDL-cholesterol, mg/dL | 51.5 (13.1) | 37.6 (9.1) | <0.001 |
Triglycerides, mg/dL | 133.6 (50.9) | 149.0 (55.8) | 0.234 |
C-reactive protein, mg/L | 4.1 (2.0) | 3.7 (1.7) | 0.334 |
sCD40L, ng/mL | 4.0 (1.5) | 5.9 (3.3) | 0.018 |
Anatomical data | |||
Nr. of vessels with obstructive disease | 0 (0.0) | 2.9 (0.8) | <0.001 |
Nr. of obstructive lesions | 0 (0.0) | 4.0 (1.4) | <0.001 |
Gensini score | 0 (0.0) | 72.9 (42.5) | <0.001 |
Data are expressed as mean (SD), except if otherwise specified. CCS - chronic coronary syndrome; HDL - high-density lipoprotein; LDL - low-density lipoprotein; Nr. - number; sCD40L - soluble CD40 ligand.